{"id":"beclometasone-dipropionate","rwe":[],"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Probable G-protein coupled receptor 97","category":"target"},{"label":"ADGRG3","category":"gene"},{"label":"NR3C1","category":"gene"},{"label":"NR3C2","category":"gene"},{"label":"A07EA07","category":"atc"},{"label":"Respiratory (Inhalation)","category":"route"},{"label":"Nasal","category":"route"},{"label":"Aerosol","category":"form"},{"label":"Spray","category":"form"},{"label":"Active","category":"status"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Asthma","category":"indication"},{"label":"Asthma management","category":"indication"},{"label":"Nasal polyp","category":"indication"},{"label":"Rhinitis","category":"indication"},{"label":"Vasomotor rhinitis","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Asthmatic Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Bronchodilator Agents","category":"pharmacology"},{"label":"Glucocorticoids","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":806.391,"date":"","count":645,"signal":"Asthma","source":"DrugCentral FAERS","actionTaken":"Reported 645 times (LLR=806)"},{"llr":386.969,"date":"","count":391,"signal":"Wheezing","source":"DrugCentral FAERS","actionTaken":"Reported 391 times (LLR=387)"},{"llr":231.677,"date":"","count":992,"signal":"Dyspnoea","source":"DrugCentral FAERS","actionTaken":"Reported 992 times (LLR=232)"},{"llr":203.965,"date":"","count":148,"signal":"Nightmare","source":"DrugCentral FAERS","actionTaken":"Reported 148 times (LLR=204)"},{"llr":159.484,"date":"","count":147,"signal":"Lip swelling","source":"DrugCentral FAERS","actionTaken":"Reported 147 times (LLR=159)"},{"llr":135.727,"date":"","count":149,"signal":"Depressed mood","source":"DrugCentral FAERS","actionTaken":"Reported 149 times (LLR=136)"},{"llr":133.26,"date":"","count":45,"signal":"Bacterial disease carrier","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=133)"},{"llr":132.784,"date":"","count":106,"signal":"Bronchospasm","source":"DrugCentral FAERS","actionTaken":"Reported 106 times (LLR=133)"},{"llr":122.603,"date":"","count":129,"signal":"Swollen tongue","source":"DrugCentral FAERS","actionTaken":"Reported 129 times (LLR=123)"},{"llr":117.513,"date":"","count":239,"signal":"Chest discomfort","source":"DrugCentral FAERS","actionTaken":"Reported 239 times (LLR=118)"},{"llr":108.819,"date":"","count":89,"signal":"Anger","source":"DrugCentral FAERS","actionTaken":"Reported 89 times (LLR=109)"},{"llr":108.237,"date":"","count":136,"signal":"Aggression","source":"DrugCentral FAERS","actionTaken":"Reported 136 times (LLR=108)"},{"llr":108.18,"date":"","count":443,"signal":"Cough","source":"DrugCentral FAERS","actionTaken":"Reported 443 times (LLR=108)"},{"llr":108.016,"date":"","count":49,"signal":"Bronchial secretion retention","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=108)"},{"llr":95.498,"date":"","count":365,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 365 times (LLR=95)"}],"commonSideEffects":[{"effect":"Nasopharyngeal irritation","drugRate":"24%","severity":"mild","organSystem":""},{"effect":"Sneezing attacks","drugRate":"4%","severity":"mild","organSystem":""},{"effect":"Headache","drugRate":"5%","severity":"mild","organSystem":""},{"effect":"Nausea","drugRate":"5%","severity":"mild","organSystem":""},{"effect":"Lightheadedness","drugRate":"5%","severity":"mild","organSystem":""},{"effect":"Nasal stuffiness","drugRate":"3%","severity":"mild","organSystem":""},{"effect":"Nosebleeds","drugRate":"3%","severity":"mild","organSystem":""},{"effect":"Rhinorrhea","drugRate":"3%","severity":"mild","organSystem":""},{"effect":"Tearing eyes","drugRate":"3%","severity":"mild","organSystem":""},{"effect":"Dryness and irritation of nose and throat","drugRate":"","severity":"mild","organSystem":""},{"effect":"Unpleasant taste","drugRate":"","severity":"mild","organSystem":""},{"effect":"Unpleasant smell","drugRate":"","severity":"mild","organSystem":""}],"contraindications":["Acute tuberculosis","Adrenal cortical hypofunction","Bacterial infectious disease","Bilateral cataracts","Disease caused by parasite","Disease of liver","Epistaxis","Exposure to varicella","Glaucoma","Inactive tuberculosis","Measles","Mycobacteriosis","Mycosis","Nasal Candidiasis","Nasal Septal Ulcers","Nasal Trauma","Ocular hypertension","Operation on nose","Ophthalmic herpes simplex","Perforation of nasal septum","Uncontrolled Bacterial Infections","Untreated Fungal Infection","Varicella-zoster virus infection"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies with QVAR REDIHALER or beclomethasone dipropionate in pregnant women. There are clinical considerations with the use of inhaled corticosteroids (ICS), including beclomethasone dipropionate, in pregnant women. Like other corticosteroids, beclomethasone dipropionate was teratogenic and embryocidal in the mouse and rabbit at subcutaneous dose of 0.1 mg/kg in mice or 0.025 mg/kg in rabbits (approximately equal to the maximum recommended daily intranasal dose in adults on mg/m2 basis). No teratogenicity or embryocidal effects were seen in rats when exposed to an inhalation dose of 0.1 mg/kg plus oral doses of up to 10 mg/kg per day for combined dose of 10.1 mg/kg (approximately equal to the maximum recommended daily intranasal dose in adults on mg/m2 basis). The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. In the US general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.","Geriatric use":"Clinical studies of BECONASE AQ Nasal Spray did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy in this population.","Paediatric use":"The safety and effectiveness of BECONASE AQ Nasal Spray have been established in children aged 6 years and above through evidence from extensive clinical use in adult and pediatric patients. The safety and effectiveness of BECONASE AQ Nasal Spray in children below 6 years of age have not been established. Controlled clinical studies have shown that intranasal corticosteroids may cause reduction in growth velocity in pediatric patients. This effect has been observed in the absence of local irritation or other adverse effects."},"seriousAdverseEvents":[{"effect":"Nasal septum perforation","drugRate":"","severity":"serious"},{"effect":"Ulceration of nasal mucosa","drugRate":"","severity":"serious"},{"effect":"Wheezing","drugRate":"","severity":"serious"},{"effect":"Cataracts","drugRate":"","severity":"serious"},{"effect":"Glaucoma","drugRate":"","severity":"serious"},{"effect":"Increased intraocular pressure","drugRate":"","severity":"serious"},{"effect":"Anaphylactoid/anaphylactic reactions","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Bronchospasm","drugRate":"","severity":"serious"},{"effect":"Growth suppression","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2041-08-19","territory":"US","patentNumber":"11583643"},{"source":"FDA Orange Book via DrugCentral","expires":"2039-07-21","territory":"US","patentNumber":"11559637"},{"source":"FDA Orange Book via DrugCentral","expires":"2039-01-25","territory":"US","patentNumber":"10792447"},{"source":"FDA Orange Book via DrugCentral","expires":"2038-01-26","territory":"US","patentNumber":"11395888"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-01-01","territory":"US","patentNumber":"10561808"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-10-21","territory":"US","patentNumber":"10188811"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-07-17","territory":"US","patentNumber":"8931476"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"10022509"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"10022510"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"10086156"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"10695512"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"11395889"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"9463289"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"9808587"},{"source":"FDA Orange Book via DrugCentral","expires":"2028-09-07","territory":"US","patentNumber":"8132712"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-01-24","territory":"US","patentNumber":"7780038"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=beclometasone dipropionate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:12:49.777201+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:12:49.777072+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:12:55.241990+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=beclometasone dipropionate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:12:55.895965+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:57.158277+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200989/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:56.811991+00:00"}},"allNames":"beconase aq","offLabel":[],"synonyms":["rhinocort","beclometasone dipropionate","beclomethasone dipropionate","beclomethasone dipropionate monohydrate"],"timeline":[{"date":"1976-05-12","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Beconase Aq (beclometasone dipropionate) is a corticosteroid medication originally developed by GlaxoSmithKline. It is a small molecule that targets the probable G-protein coupled receptor 97 and is used to treat various respiratory conditions, including allergic rhinitis, asthma, and nasal polyps. Beconase Aq was first approved by the FDA in 1976 and is still commercially available. Key safety considerations include potential local side effects such as nasal irritation and systemic effects like adrenal suppression. The medication's commercial status is not explicitly stated, but it is likely to be off-patent.","brandName":"Beconase Aq","ecosystem":[{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Asthma","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"budesonide","slug":"budesonide","company":""}],"globalPrevalence":262000000},{"indication":"Asthma management","otherDrugs":[{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"budesonide","slug":"budesonide","company":""},{"name":"ciclesonide","slug":"ciclesonide","company":"Takeda Gmbh"},{"name":"cromoglicic acid","slug":"cromoglicic-acid","company":"King Pharms"}],"globalPrevalence":262000000},{"indication":"Nasal polyp","otherDrugs":[],"globalPrevalence":null},{"indication":"Rhinitis","otherDrugs":[{"name":"clofedanol","slug":"clofedanol","company":""},{"name":"codeine","slug":"codeine","company":"Ani Pharms"},{"name":"dextromethorphan","slug":"dextromethorphan","company":"Ani Pharms"},{"name":"dihydrocodeine","slug":"dihydrocodeine","company":"Caraco"}],"globalPrevalence":null},{"indication":"Vasomotor rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"azelastine","slug":"azelastine","company":"Meda Pharms"}],"globalPrevalence":null}],"mechanism":{"target":"Probable G-protein coupled receptor 97","novelty":"Follow-on","targets":[{"gene":"ADGRG3","source":"DrugCentral","target":"Probable G-protein coupled receptor 97","protein":"Adhesion G protein-coupled receptor G3"},{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"NR3C2","source":"DrugCentral","target":"Mineralocorticoid receptor","protein":"Mineralocorticoid receptor"},{"gene":"PGR","source":"DrugCentral","target":"Progesterone receptor","protein":"Progesterone receptor"},{"gene":"MMP9","source":"DrugCentral","target":"Matrix metalloproteinase-9","protein":"Matrix metalloproteinase-9"},{"gene":"IL5","source":"DrugCentral","target":"Interleukin-5","protein":"Interleukin-5"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid","explanation":"","oneSentence":"","technicalDetail":"Beclometasone dipropionate is a potent corticosteroid that exerts its effects by binding to the probable G-protein coupled receptor 97, leading to the inhibition of pro-inflammatory cytokines and the promotion of anti-inflammatory responses."},"commercial":{"launchDate":"1976","_launchSource":"DrugCentral (FDA 1976-05-12, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/294","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=beclometasone%20dipropionate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=beclometasone dipropionate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:55:06.986879","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:58.473364+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"prednisolone","drugSlug":"prednisolone","fdaApproval":"1955-06-21","genericCount":42,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"hydrocortisone","drugSlug":"hydrocortisone","fdaApproval":"1952-08-05","patentExpiry":"Nov 19, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"prednisone","drugSlug":"prednisone","fdaApproval":"1955-02-21","patentExpiry":"Jan 7, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"budesonide","drugSlug":"budesonide","fdaApproval":"1994-02-14","patentExpiry":"Sep 9, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"beclometasone dipropionate","indications":{"approved":[{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Asthma","source":"DrugCentral","snomedId":195967001,"regulator":"FDA","eligibility":"Not explicitly mentioned as a separate indication, but Asthma management is mentioned. No age or stage restrictions mentioned.","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Asthma management","source":"DrugCentral","snomedId":406162001,"regulator":"FDA","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Nasal polyp","source":"DrugCentral","snomedId":52756005,"regulator":"FDA"},{"name":"Rhinitis","source":"DrugCentral","snomedId":70076002,"regulator":"FDA","eligibility":"Nonallergic (vasomotor) rhinitis patients. No age or stage restrictions mentioned."},{"name":"Vasomotor rhinitis","source":"DrugCentral","snomedId":8229003,"regulator":"FDA"}],"offLabel":[{"name":"Severe chronic obstructive pulmonary disease","source":"DrugCentral","drugName":"beclometasone dipropionate","evidenceCount":90,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"prednisolone","brandName":"prednisolone","genericName":"prednisolone","approvalYear":"1955","relationship":"same-class"},{"drugId":"hydrocortisone","brandName":"hydrocortisone","genericName":"hydrocortisone","approvalYear":"1952","relationship":"same-class"},{"drugId":"prednisone","brandName":"prednisone","genericName":"prednisone","approvalYear":"1955","relationship":"same-class"},{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-class"},{"drugId":"budesonide","brandName":"budesonide","genericName":"budesonide","approvalYear":"1994","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04886999","phase":"PHASE3","title":"Study in Adult Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-24","conditions":["Asthma"],"enrollment":78,"completionDate":"2023-02-01"},{"nctId":"NCT07489911","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)","status":"RECRUITING","sponsor":"Chiesi Slovenija, d.o.o.","startDate":"2024-11-04","conditions":["Asthma","Asthma Patients","Asthma Bronchiale"],"enrollment":200,"completionDate":"2026-07"},{"nctId":"NCT06786767","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting","status":"COMPLETED","sponsor":"Chiesi Bulgaria","startDate":"2025-02-01","conditions":["Asthma","Asthma Patients","Asthma Bronchiale"],"enrollment":281,"completionDate":"2026-01-05"},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":["Asthma"],"enrollment":542,"completionDate":"2012-11-29"},{"nctId":"NCT03963167","phase":"","title":"Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2019-08-21","conditions":["COPD"],"enrollment":661,"completionDate":"2022-03-04"},{"nctId":"NCT05168995","phase":"","title":"Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2022-04-12","conditions":["Asthma"],"enrollment":620,"completionDate":"2024-02-09"},{"nctId":"NCT05888350","phase":"NA","title":"Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2023-04-01","conditions":["Cough"],"enrollment":502,"completionDate":"2025-04-30"},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":["Asthma"],"enrollment":20,"completionDate":"2030-12-31"},{"nctId":"NCT07406048","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Farmaceutica Ltda.","startDate":"2026-01-30","conditions":["COPD (Chronic Obstructive Pulmonary Disease)"],"enrollment":396,"completionDate":"2027-06-30"},{"nctId":"NCT04320342","phase":"PHASE3","title":"A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-04-28","conditions":["COPD","COPD Exacerbation"],"enrollment":3433,"completionDate":"2026-01-12"},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":["Chronic GVHD"],"enrollment":10,"completionDate":"2024-10-01"},{"nctId":"NCT07301736","phase":"PHASE2","title":"Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-12-17","conditions":["Asthma"],"enrollment":780,"completionDate":"2027-06-03"},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":["COPD"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT06480890","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2024-07-02","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":362,"completionDate":"2025-09-12"},{"nctId":"NCT07232264","phase":"NA","title":"Respiratory and Peripheral Muscle Strength as Predictors of Inhaler Treatment Response in Asthma: A Comparison of DPI and MDI Devices","status":"COMPLETED","sponsor":"Bugra Kerget","startDate":"2025-03-01","conditions":["Asthma (Diagnosis)"],"enrollment":80,"completionDate":"2025-09-24"},{"nctId":"NCT02114034","phase":"","title":"Cohort Analysis of Clinical and Biological Severe Childhood Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-11-12","conditions":["Severe Asthma"],"enrollment":362,"completionDate":"2032-11"},{"nctId":"NCT04902573","phase":"","title":"A Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Out-comes","status":"COMPLETED","sponsor":"Chiesi UK","startDate":"2021-06-17","conditions":["Asthma"],"enrollment":147,"completionDate":"2024-06-14"},{"nctId":"NCT06970080","phase":"PHASE4","title":"Therapeutic Relevance of Abnormal Airway Morphology in Asthma","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-02","conditions":["Asthma"],"enrollment":242,"completionDate":"2028-06"},{"nctId":"NCT05292586","phase":"PHASE3","title":"A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-08-31","conditions":["Asthma"],"enrollment":1377,"completionDate":"2024-06-24"},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":["COPD (Chronic Obstructive Pulmonary Disease)","Acupuncture"],"enrollment":60,"completionDate":"2026-01-15"},{"nctId":"NCT06100042","phase":"","title":"Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chiesi Italia","startDate":"2024-04-24","conditions":["Asthma"],"enrollment":200,"completionDate":"2026-06-30"},{"nctId":"NCT04937543","phase":"PHASE2","title":"Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2021-06-28","conditions":["Covid19"],"enrollment":50,"completionDate":"2022-05-20"},{"nctId":"NCT03141424","phase":"PHASE4","title":"Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2022-06-01","conditions":["Asthma"],"enrollment":20,"completionDate":"2024-10-25"},{"nctId":"NCT06869382","phase":"PHASE4","title":"ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression","status":"COMPLETED","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2023-01-01","conditions":["Asthma Patients"],"enrollment":26,"completionDate":"2024-03-31"},{"nctId":"NCT06234345","phase":"PHASE3","title":"Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":1252,"completionDate":"2028-08"},{"nctId":"NCT03888131","phase":"PHASE3","title":"Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-07-30","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":750,"completionDate":"2022-05-06"},{"nctId":"NCT05018598","phase":"PHASE4","title":"Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-25","conditions":["Asthma"],"enrollment":320,"completionDate":"2024-04-16"},{"nctId":"NCT05898984","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-04-24","conditions":["Asthma"],"enrollment":69,"completionDate":"2023-07-14"},{"nctId":"NCT00476268","phase":"PHASE3","title":"Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-02","conditions":["Asthma"],"enrollment":824,"completionDate":"2005-01"},{"nctId":"NCT05830071","phase":"PHASE1","title":"A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-03-29","conditions":["Asthma","Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":95,"completionDate":"2023-10-13"},{"nctId":"NCT00395408","phase":"PHASE4","title":"Linear Growth Study (0476-097)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-06","conditions":["Asthma"],"enrollment":360,"completionDate":"2003-12"},{"nctId":"NCT06482294","phase":"PHASE2","title":"CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Università degli Studi di Ferrara","startDate":"2024-06-18","conditions":["Asthma"],"enrollment":80,"completionDate":"2025-07-01"},{"nctId":"NCT05948891","phase":"","title":"Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study","status":"RECRUITING","sponsor":"Chiesi SAS","startDate":"2023-08-01","conditions":["COPD"],"enrollment":500,"completionDate":"2025-03"},{"nctId":"NCT04817800","phase":"PHASE1,PHASE2","title":"To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2021-03-25","conditions":["Seasonal Allergic Rhinitis"],"enrollment":48,"completionDate":"2021-04-10"},{"nctId":"NCT03453112","phase":"PHASE3","title":"Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-10-09","conditions":["Asthma"],"enrollment":494,"completionDate":"2021-12-28"},{"nctId":"NCT06139029","phase":"EARLY_PHASE1","title":"Comparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis","status":"COMPLETED","sponsor":"Mardan Medical Complex","startDate":"2022-11-15","conditions":["Acute Bronchiolitis"],"enrollment":60,"completionDate":"2023-03-15"},{"nctId":"NCT05097014","phase":"PHASE4","title":"CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-28","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":106,"completionDate":"2023-02-24"},{"nctId":"NCT02517099","phase":"PHASE2","title":"Preschool Wheeze: Inflammation/Infection Guided Management","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-06-05","conditions":["Asthma"],"enrollment":60,"completionDate":"2018-08-17"},{"nctId":"NCT03846570","phase":"PHASE3","title":"Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2019-01-29","conditions":["Bronchiectasis"],"enrollment":34,"completionDate":"2022-07-05"},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":26839,"completionDate":"2022-06-30"},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":843,"completionDate":"2022-10-26"},{"nctId":"NCT03795350","phase":"PHASE1","title":"Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2019-01-14","conditions":["Chronic Obstructive Pulmonary Disease","Asthma"],"enrollment":19,"completionDate":"2020-04-03"},{"nctId":"NCT04873063","phase":"PHASE1","title":"Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers","status":"COMPLETED","sponsor":"SOFAR S.p.A.","startDate":"2021-10-22","conditions":["Healthy Adult Male Volunteers"],"enrollment":28,"completionDate":"2022-04-28"},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":["Asthma"],"enrollment":0,"completionDate":"2013-09"},{"nctId":"NCT03855189","phase":"PHASE3","title":"Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1993-08-23","conditions":["Seasonal Allergic Rhinitis"],"enrollment":345,"completionDate":"1993-10-22"},{"nctId":"NCT03879772","phase":"PHASE3","title":"Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1996-03-12","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":679,"completionDate":"1996-07-01"},{"nctId":"NCT04671355","phase":"PHASE4","title":"TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD","status":"WITHDRAWN","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-04","conditions":["COPD"],"enrollment":0,"completionDate":"2022-02-18"},{"nctId":"NCT04876677","phase":"PHASE3","title":"Functional Respiratory Imaging Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-05-25","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":25,"completionDate":"2022-01-03"},{"nctId":"NCT03084718","phase":"PHASE2","title":"An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":["Asthma"],"enrollment":610,"completionDate":"2018-12-05"},{"nctId":"NCT00109668","phase":"PHASE3","title":"Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-07-31","conditions":["Asthma"],"enrollment":415,"completionDate":"2006-09-30"},{"nctId":"NCT01024608","phase":"PHASE3","title":"Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-12-31","conditions":["Seasonal Allergic Rhinitis","Hay Fever"],"enrollment":340,"completionDate":"2010-02-28"},{"nctId":"NCT00988247","phase":"PHASE3","title":"Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-10-31","conditions":["Rhinitis, Allergic, Perennial"],"enrollment":529,"completionDate":"2011-02-28"},{"nctId":"NCT00250341","phase":"PHASE4","title":"Non-invasive Measures of Distal Lung Disease in Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-09-30","conditions":["Asthma"],"enrollment":34,"completionDate":"2007-09-30"},{"nctId":"NCT00071552","phase":"PHASE4","title":"Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-01-31","conditions":["Asthma"],"enrollment":49,"completionDate":"2006-07-31"},{"nctId":"NCT00094016","phase":"PHASE3","title":"Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-10-31","conditions":["Asthma"],"enrollment":440,"completionDate":"2006-06-30"},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":["Asthma"],"enrollment":787,"completionDate":"2015-09"},{"nctId":"NCT05114434","phase":"","title":"Effect of BDP/Formoterol/G on Cough Efficacy in Moderate to Severe COPD Patients (EFFICACE)","status":"UNKNOWN","sponsor":"University of Parma","startDate":"2021-11","conditions":["COPD, Chronic Obstructive Pulmonary Disease"],"enrollment":40,"completionDate":"2023-06"},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":["Asthma"],"enrollment":1113,"completionDate":"2014-12"},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":["Persistent Asthma"],"enrollment":273,"completionDate":"2014-12-24"},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":["Asthma"],"enrollment":628,"completionDate":"2016-03"},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":["Persistent Asthma"],"enrollment":713,"completionDate":"2016-03-31"},{"nctId":"NCT02030457","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":["Pharmacokinetics"],"enrollment":72,"completionDate":"2014-06"},{"nctId":"NCT02119234","phase":"PHASE1","title":"Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-03","conditions":["COPD"],"enrollment":36,"completionDate":"2015-02"},{"nctId":"NCT00929851","phase":"PHASE3","title":"BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-10","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":1199,"completionDate":"2012-07"},{"nctId":"NCT02467452","phase":"PHASE3","title":"Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":1479,"completionDate":"2017-01"},{"nctId":"NCT01917331","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-03","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":1368,"completionDate":"2016-03"},{"nctId":"NCT01343745","phase":"PHASE2","title":"Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2008-02","conditions":["Mild Persistent Asthma"],"enrollment":18,"completionDate":"2008-08"},{"nctId":"NCT01911364","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":3686,"completionDate":"2016-03"},{"nctId":"NCT01176747","phase":"PHASE1,PHASE2","title":"Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-08","conditions":["Pulmonary Disease, Chronic Obstructive","Asthma"],"enrollment":28,"completionDate":"2010-10"},{"nctId":"NCT02040597","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":42,"completionDate":"2015-04"},{"nctId":"NCT01738087","phase":"PHASE2","title":"Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-11","conditions":["Asthmatic"],"enrollment":30,"completionDate":"2013-01"},{"nctId":"NCT00476099","phase":"PHASE3","title":"Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-12","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":828,"completionDate":"2008-11"},{"nctId":"NCT00000752","phase":"PHASE2","title":"Preventing Frequent Sinus Infections in HIV-Infected Patients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Sinusitis"],"enrollment":0,"completionDate":"1993-02"},{"nctId":"NCT03590379","phase":"PHASE2","title":"Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-06-15","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":366,"completionDate":"2019-03-06"},{"nctId":"NCT02676076","phase":"PHASE3","title":"TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-02-17","conditions":["Asthma"],"enrollment":1153,"completionDate":"2018-05-17"},{"nctId":"NCT02676089","phase":"PHASE3","title":"TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-04-06","conditions":["Asthma"],"enrollment":1433,"completionDate":"2018-05-28"},{"nctId":"NCT02127866","phase":"PHASE2","title":"Triple in Asthma Dose Finding","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-04","conditions":["Asthma"],"enrollment":211,"completionDate":"2015-03"},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":["COPD (Chronic Obstructive Pulmonary Disease)"],"enrollment":990,"completionDate":"2020-05-26"},{"nctId":"NCT02687100","phase":"PHASE4","title":"The Effects of Beclomethasone Upper the Endotracheal Cuff on the Occurrence of Sore Throat at Extubation","status":"WITHDRAWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2016-10","conditions":["Anesthesia, Endotracheal"],"enrollment":0,"completionDate":"2017-09"},{"nctId":"NCT04737655","phase":"PHASE4","title":"Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care","status":"UNKNOWN","sponsor":"PARZIBUT Gilles","startDate":"2021-02-15","conditions":["COPD Exacerbation"],"enrollment":200,"completionDate":"2023-05-15"},{"nctId":"NCT00489203","phase":"PHASE2","title":"Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-04","conditions":["Hematopoietic/Lymphoid Cancer","Accelerated Phase Chronic Myelogenous Leukemia","Adult Acute Lymphoblastic Leukemia in Remission","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Atypical Chronic Myeloid Leukemia","Blastic Phase Chronic Myelogenous Leukemia","Childhood Acute Lymphoblastic Leukemia in Remission","Childhood Acute Myeloid Leukemia in Remission","Childhood Chronic Myelogenous Leukemia","Childhood Myelodysplastic Syndromes","Chronic Eosinophilic Leukemia","Chronic Myelomonocytic Leukemia","Chronic Neutrophilic Leukemia","Chronic Phase Chronic Myelogenous Leukemia","Contiguous Stage II Adult Burkitt Lymphoma","Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Contiguous Stage II Adult Lymphoblastic Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Mantle Cell Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","de Novo Myelodysplastic Syndromes","Essential Thrombocythemia","Extramedullary Plasmacytoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Graft Versus Host Disease","Isolated Plasmacytoma of Bone","Juvenile Myelomonocytic Leukemia","Meningeal Chronic Myelogenous Leukemia","Myelodysplastic/Myeloproliferative Disease, Unclassifiable","Nodal Marginal Zone B-cell Lymphoma","Noncontiguous Stage II Adult Burkitt Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Adult Lymphoblastic Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Previously Treated Myelodysplastic Syndromes","Primary Myelofibrosis","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Acute Myeloid Leukemia","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Adult T-cell Leukemia/Lymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Mycosis Fungoides/Sezary Syndrome","Recurrent Small Lymphocytic Lymphoma","Recurrent/Refractory Childhood Hodgkin Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Hairy Cell Leukemia","Relapsing Chronic Myelogenous Leukemia","Secondary Myelodysplastic Syndromes","Stage I Adult Burkitt Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Mixed Cell Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Adult Hodgkin Lymphoma","Stage I Adult Immunoblastic Large Cell Lymphoma","Stage I Adult Lymphoblastic Lymphoma","Stage I Adult T-cell Leukemia/Lymphoma","Stage I Childhood Hodgkin Lymphoma","Stage I Chronic Lymphocytic Leukemia","Stage I Cutaneous T-cell Non-Hodgkin Lymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Mantle Cell Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Multiple Myeloma","Stage I Mycosis Fungoides/Sezary Syndrome","Stage I Small Lymphocytic Lymphoma","Stage II Adult Hodgkin Lymphoma","Stage II Adult T-cell Leukemia/Lymphoma","Stage II Chronic Lymphocytic Leukemia","Stage II Cutaneous T-cell Non-Hodgkin Lymphoma","Stage II Multiple Myeloma","Stage II Mycosis Fungoides/Sezary Syndrome","Stage III Adult Burkitt Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Mixed Cell Lymphoma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Hodgkin Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Adult Lymphoblastic Lymphoma","Stage III Adult T-cell Leukemia/Lymphoma","Stage III Chronic Lymphocytic Leukemia","Stage III Cutaneous T-cell Non-Hodgkin Lymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage III Marginal Zone Lymphoma","Stage III Multiple Myeloma","Stage III Mycosis Fungoides/Sezary Syndrome","Stage III Small Lymphocytic Lymphoma","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Mixed Cell Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Hodgkin Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Adult Lymphoblastic Lymphoma","Stage IV Adult T-cell Leukemia/Lymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IV Mycosis Fungoides/Sezary Syndrome","Stage IV Small Lymphocytic Lymphoma"],"enrollment":140,"completionDate":""},{"nctId":"NCT04051710","phase":"PHASE3","title":"Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH","status":"COMPLETED","sponsor":"Aurobindo Pharma Ltd","startDate":"2019-03-12","conditions":["Bronchial Asthma"],"enrollment":1550,"completionDate":"2019-12-20"},{"nctId":"NCT00557180","phase":"","title":"Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2007-10","conditions":["Asthma","Obesity"],"enrollment":33,"completionDate":"2011-02"},{"nctId":"NCT00497523","phase":"PHASE3","title":"Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-03","conditions":["Bronchial Asthma"],"enrollment":283,"completionDate":"2007-01"},{"nctId":"NCT00413387","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":["Bronchial Asthma"],"enrollment":219,"completionDate":"2005-10"},{"nctId":"NCT00382889","phase":"PHASE3","title":"As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2002-08","conditions":["Asthma"],"enrollment":480,"completionDate":"2004-09"},{"nctId":"NCT00394368","phase":"PHASE3","title":"EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-11","conditions":["Bronchial Asthma"],"enrollment":180,"completionDate":"2005-09"},{"nctId":"NCT01349257","phase":"PHASE2","title":"Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-05","conditions":["Asthma"],"enrollment":24,"completionDate":"2011-06"},{"nctId":"NCT01848769","phase":"PHASE2","title":"Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-09","conditions":["Asthma"],"enrollment":20,"completionDate":"2010-12"},{"nctId":"NCT01468272","phase":"PHASE2","title":"Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-11","conditions":["Asthma in Children"],"enrollment":26,"completionDate":"2012-08"},{"nctId":"NCT01803087","phase":"PHASE2","title":"Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-02","conditions":["Asthma"],"enrollment":60,"completionDate":"2012-10"},{"nctId":"NCT01191424","phase":"PHASE2","title":"A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-10","conditions":["Asthma"],"enrollment":57,"completionDate":"2011-09"},{"nctId":"NCT04421742","phase":"","title":"The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.","status":"COMPLETED","sponsor":"Alfredo Antonio Chetta","startDate":"2017-05-31","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":43,"completionDate":"2019-05-23"},{"nctId":"NCT03268226","phase":"PHASE3","title":"Functional Respiratory Imaging Study (FRI)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-11-20","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":20,"completionDate":"2019-01-30"},{"nctId":"NCT03842904","phase":"PHASE4","title":"A Study Comparing the Effects of Trimbow to Fostair in COPD","status":"COMPLETED","sponsor":"Medicines Evaluation Unit Ltd","startDate":"2018-12-13","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":23,"completionDate":"2019-08-06"},{"nctId":"NCT02509299","phase":"NA","title":"Effect of Physiotherapy in Hospitalized COPD Patients","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2019-09-01","conditions":["COPD"],"enrollment":49,"completionDate":"2019-12-14"},{"nctId":"NCT03562949","phase":"PHASE3","title":"A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol","status":"TERMINATED","sponsor":"Amneal Ireland Limited","startDate":"2018-12-06","conditions":["Asthma"],"enrollment":761,"completionDate":"2019-08-02"},{"nctId":"NCT01894048","phase":"PHASE4","title":"Targeted Small Airways Therapy in Persistent Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2013-10-28","conditions":["Asthma"],"enrollment":26,"completionDate":"2018-06-25"},{"nctId":"NCT03834012","phase":"PHASE3","title":"Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma","status":"WITHDRAWN","sponsor":"Adamis Pharmaceuticals Corporation","startDate":"2019-02","conditions":["Asthma"],"enrollment":0,"completionDate":"2020-04"},{"nctId":"NCT03835871","phase":"PHASE3","title":"Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma","status":"WITHDRAWN","sponsor":"Adamis Pharmaceuticals Corporation","startDate":"2019-02","conditions":["Asthma"],"enrollment":0,"completionDate":"2020-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Respiratory (Inhalation), Nasal","formulation":"Aerosol, Spray","formulations":[{"form":"AEROSOL, METERED","route":"NASAL","productName":"QNASL"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"QVAR"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"QVAR REDIHALER"},{"form":"SPRAY, SUSPENSION","route":"NASAL","productName":"BECONASE  AQ"},{"form":"SPRAY, SUSPENSION","route":"NASAL","productName":"BECONASEAQ"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"1167","NDDF":"002179","UNII":"5B307S63B2","CHEBI":"CHEBI:3002","VANDF":"4018793","INN_ID":"2307","RXNORM":"1347","UMLSCUI":"C0004906","chemblId":"CHEMBL1200989","ChEMBL_ID":"CHEMBL1200500","KEGG_DRUG":"D00689","DRUGBANK_ID":"DB00394","PUBCHEM_CID":"21700","SNOMEDCT_US":"116574000","IUPHAR_LIGAND_ID":"5894","SECONDARY_CAS_RN":"77011-63-3","MESH_DESCRIPTOR_UI":"D019819"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.5 hours","clearance":"36.0 mL/min/kg","fractionUnbound":"0.13%","volumeOfDistribution":"0.29 L/kg"},"publicationCount":168,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A07EA07","allCodes":["A07EA07","D07AC15","D07CC04","R01AD01","R03AK08","R03AK13","R03AL09","R03BA01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"1976","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"7780038","territory":"US","patent_type":null,"expiry_date":"2027-01-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8132712","territory":"US","patent_type":null,"expiry_date":"2028-09-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10695512","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9463289","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9808587","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10086156","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10022509","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10022510","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11395889","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8931476","territory":"US","patent_type":null,"expiry_date":"2031-07-17T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10188811","territory":"US","patent_type":null,"expiry_date":"2031-10-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10561808","territory":"US","patent_type":null,"expiry_date":"2032-01-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11395888","territory":"US","patent_type":null,"expiry_date":"2038-01-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10792447","territory":"US","patent_type":null,"expiry_date":"2039-01-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11559637","territory":"US","patent_type":null,"expiry_date":"2039-07-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11583643","territory":"US","patent_type":null,"expiry_date":"2041-08-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:58.473364+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}